Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Tisseel		Hospital use only
Tobramycin nebulised		NHS England Commissioned for Cystic Fibrosis only. Existing patients - initiated prior to April 2013
Tobramycin nebulised		NHS England Commissioned for Cystic Fibrosis only, new patients
Tocilizumab (Roactemra)	TA247 - Rheumatoid arthritis - tocilizumab (rapid review TA198) TA238 - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	Hospital use only
Tolterodine M/R capsules		High relative cost. Second line.
Tolvaptan (Jinarc®)	TA358 - Tolvaptan for treating autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease
Tolvaptan (Samsca®)		Consultant advice only. Tolvaptan (Samsca) for the treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Topiramate tablets		Prophylaxis of migraine. Specialist recommendation.
Topotecan capsules	TA184 - Topotecan for the treatment of relapsed small-cell lung cancer	For hospital use only
Tramadol capsules		Second line after morphine and codeine. Soluble tablets - high relative cost - patients with swallowing difficulties.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.